The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 1, 2001, Pages 15-22

  Thorburn, Christine E ^a   Edwards, David I ^a  

^a UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; ERADICATION THERAPY; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PARAMETER; PHARMACOKINETICS; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034924244     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.1.15     Document Type: Article

References (28)

1. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
2. Results of the Alexander Project: A continuing, multi-center study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens
3. Multiple antibiotic resistance in Streptococcus pneumoniae
4. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
5. The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens
6. Application of fluoroquinolone pharmacodynamics
7. Pharmacokinetics and pharmacodynamics of fluoroquinolones
8. Evaluation of the activity of the newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae
9. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae
10. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
11. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: Effect of simultaneous versus staggered administration in an in vitro model of infection
12. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection
13. In vitro activity of sparfloxacin, a new quinolone antimicrobial agent
14. Interaction between oral sparfloxacin and antacid in normal volunteers
15. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin
16. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity
17. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers
18. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: Relevance for drug efficacy
19. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae
20. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
21. Primary targets of fluoroquinolones in Streptococcus pneumoniae
22. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
23. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
24. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
25. Differential behaviours of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases
26. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: Comparison with ciprofloxacin, sparfloxacin and ofloxacin
27. Pharmacokinetics and tissue penetration of ciprofloxacin
28. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro